Eoin McKinney

Predictimmune Ltd. develops tools for guiding treatment options in immune-mediated inflammatory diseases. It offers PredictSURE IBD is a biomarker test, combined with a sophisticated, proprietary algorithm that will tell the likely course of newly diagnosed patients’ IBD, differentiating between an aggressive or milder form of the disease. The company was founded in May 2017 and is headquartered in Cambridge, the United Kingdom.

Predictimmune Ltd. develops tools for guiding treatment options in immune-mediated inflammatory diseases. It offers PredictSURE IBD is a biomarker test, combined with a sophisticated, proprietary algorithm that will tell the likely course of newly diagnosed patients’ IBD, differentiating between an aggressive or milder form of the disease. The company was founded in May 2017 and is headquartered in Cambridge, the United Kingdom.

Predictimmune Ltd. develops tools for guiding treatment options in immune-mediated inflammatory diseases. It offers PredictSURE IBD is a biomarker test, combined with a sophisticated, proprietary algorithm that will tell the likely course of newly diagnosed patients’ IBD, differentiating between an aggressive or milder form of the disease. The company was founded in May 2017 and is headquartered in Cambridge, the United Kingdom.